Plan Combines Bitcoin Treasury Strategy and Equity Line to Support 2026 Potential Monetization Events, Starting with Pearsanta’s Planned IPO
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced “bit by bio”) Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt’s capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026.
Aditxt is a social innovation platform that currently operates two programs focused on autoimmunity and early disease and cancer detection. The Company seeks to grow by Acquiring, Building, and Capitalizing high-growth ventures across health and biotechnology. The bitXbio Plan marks a deliberate move to broaden the company’s capital accessibility and align its current market value with its commercialization roadmap — blending Bitcoin-backed reserve with capital access to support scale and liquidity.
“bitXbio™ is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline,” said Amro Albanna, Co-founder and CEO of Aditxt. “As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds, and continue to utilize our equity line to support the commercialization of high-impact innovations. We believe that this approach positions us to unlock shareholder value as we strive to execute on planned monetization milestones, starting in 2026.”
Plan Highlights
- Bitcoin-Backed Treasury Strategy
Aditxt plans to establish a Bitcoin reserve, subject to the availability of funds, to align its market value in support of its commercialization activities, and to unlock a new class of opportunities with digital asset economies.
- Equity Line Facility
Aditxt intends to strategically deploy capital drawn on its existing equity line facility to meet its existing financial obligations and in support of its commercialization roadmap and upcoming monetization events. Aditxt has approximately $125 million in availability under its common stock purchase agreement with its equity line investor, of which it presently has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025.
- Planned Capitalization Events in 2026
As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering.
The plan reflects Aditxt’s broader vision to build a global, socially driven biotech platform, capable of commercializing and monetizing innovation through digital capitalization.
